JP2017514854A - 抗ａｎｇ２抗体を用いる方法 - Google Patents

抗ａｎｇ２抗体を用いる方法 Download PDF

Info

Publication number
JP2017514854A
JP2017514854A JP2016566641A JP2016566641A JP2017514854A JP 2017514854 A JP2017514854 A JP 2017514854A JP 2016566641 A JP2016566641 A JP 2016566641A JP 2016566641 A JP2016566641 A JP 2016566641A JP 2017514854 A JP2017514854 A JP 2017514854A
Authority
JP
Japan
Prior art keywords
cancer
antibody
ang2
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514854A5 (enExample
Inventor
ライ，ドミニク
シコルシキ，ロバート
ハイマン，デビッド
リズビ，ネイヤー，エー．
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2017514854A publication Critical patent/JP2017514854A/ja
Publication of JP2017514854A5 publication Critical patent/JP2017514854A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016566641A 2014-05-07 2015-05-06 抗ａｎｇ２抗体を用いる方法 Pending JP2017514854A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461989884P 2014-05-07 2014-05-07
US61/989,884 2014-05-07
US201462005525P 2014-05-30 2014-05-30
US62/005,525 2014-05-30
PCT/US2015/029447 WO2015171747A1 (en) 2014-05-07 2015-05-06 Methods of using anti-ang2 antibodies

Publications (2)

Publication Number Publication Date
JP2017514854A true JP2017514854A (ja) 2017-06-08
JP2017514854A5 JP2017514854A5 (enExample) 2018-06-14

Family

ID=54392949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566641A Pending JP2017514854A (ja) 2014-05-07 2015-05-06 抗ａｎｇ２抗体を用いる方法

Country Status (12)

Country Link
US (1) US20170058025A1 (enExample)
EP (1) EP3139956A4 (enExample)
JP (1) JP2017514854A (enExample)
KR (1) KR20170003651A (enExample)
CN (1) CN107206067A (enExample)
AU (1) AU2015256052A1 (enExample)
CA (1) CA2946906A1 (enExample)
HK (1) HK1244445A1 (enExample)
IL (1) IL248391A0 (enExample)
RU (1) RU2016147521A (enExample)
SG (1) SG11201609168PA (enExample)
WO (1) WO2015171747A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226178A1 (ja) 2019-05-08 2020-11-12 ダイキン工業株式会社 フルオロポリマーの製造方法及びフルオロポリマー

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
CN109863171B (zh) 2016-08-23 2023-08-04 免疫医疗有限公司 抗vegf-a和抗ang2抗体及其用途
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
SG11202108832XA (en) * 2019-02-25 2021-09-29 Pharmabcine Inc Anti-ang2 antibody and use thereof
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510632A (ja) * 2008-01-28 2011-04-07 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
JP2013520442A (ja) * 2010-02-23 2013-06-06 ジェネンテック， インコーポレイテッド 卵巣癌の治療のための抗血管新生治療
WO2014025813A1 (en) * 2012-08-07 2014-02-13 Genentech, Inc. Combination therapy for the treatment of glioblastoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
CN102250247B (zh) * 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
WO2013078248A1 (en) * 2011-11-21 2013-05-30 General Instrument Corporation Implicit determination and combined implicit and explicit determination of collocated picture for temporal prediction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510632A (ja) * 2008-01-28 2011-04-07 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
JP2013520442A (ja) * 2010-02-23 2013-06-06 ジェネンテック， インコーポレイテッド 卵巣癌の治療のための抗血管新生治療
WO2014025813A1 (en) * 2012-08-07 2014-02-13 Genentech, Inc. Combination therapy for the treatment of glioblastoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.30, No.15 suppl., JPN6019006492, 2012, pages 3032, ISSN: 0004126504 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.32，No.15 suppl., JPN6019006494, 20 May 2014 (2014-05-20), pages 3012, ISSN: 0003985423 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226178A1 (ja) 2019-05-08 2020-11-12 ダイキン工業株式会社 フルオロポリマーの製造方法及びフルオロポリマー

Also Published As

Publication number Publication date
WO2015171747A1 (en) 2015-11-12
HK1244445A1 (zh) 2018-08-10
RU2016147521A (ru) 2018-06-09
CN107206067A (zh) 2017-09-26
KR20170003651A (ko) 2017-01-09
SG11201609168PA (en) 2016-12-29
EP3139956A4 (en) 2017-11-29
RU2016147521A3 (enExample) 2018-12-27
US20170058025A1 (en) 2017-03-02
IL248391A0 (en) 2016-11-30
CA2946906A1 (en) 2015-11-12
AU2015256052A1 (en) 2016-11-10
EP3139956A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
JP2017514854A (ja) 抗ａｎｇ２抗体を用いる方法
JP7689552B2 (ja) 核酸ポリペプチド組成物およびその使用
CN109715805B (zh) 核酸-多肽组合物及其用途
Shimamoto et al. Peptibodies: A flexible alternative format to antibodies
CN106905429A (zh) 结合SPARC的scFv
EP4414381A1 (en) Il-10 monomer fusion protein and use thereof
US11298385B2 (en) Microorganism for delivering drug for treatment of gastrointestinal disease, which expresses and secretes P8 protein, and pharmaceutical composition for preventing or treating gastrointestinal disease, which includes the same
Choi et al. Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment
JP7391971B2 (ja) 新規のｄｎａアプタマー及びこれの用途
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
US20230242606A1 (en) Cxcl9 and variants thereof for immunotherapy of cancer diseases
CN116802303A (zh) 用于预防和治疗癌症的沙门氏菌菌株及其用途
KR20220148188A (ko) 압타머 및 이의 용도
US20230212247A1 (en) Modified cxcl10 for immunotherapy of cancer diseases
CN115177728A (zh) Mapk/erk通路激活导致的癌症的治疗方法和应用及crept-cdk9复合物
WO2024180283A1 (en) Novel dosage regimen for an oncolytic adenoviral vector
HK40019322B (zh) 核酸-多肽组合物及其用途
HK40032622B (zh) 核酸-多肽组合物及其用途
HK40019322A (en) Nucleic acid-polypeptide compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191008